Metrikler
Yayın
51
Açık Erişim
19
BM Sürdürülebilir Kalkınma Amaçları
Makaleler
Tümü (50)
SCI-E, SSCI, AHCI (41)
SCI-E, SSCI, AHCI, ESCI (47)
ESCI (5)
Scopus (48)
TRDizin (9)
2025
20251. The lactate dehydrogenase-to-albumin ratio is a prognostic biomarker in extensive-stage small-cell lung cancer
YILMAZ F., Yaşar S., Tatar O. D., Yildirim H. c., Guven D. C., TABAN H., et al.
Acta Medica
, cilt.56, sa.3, ss.186-198, 2025 (TRDizin)
2025
20252. Artificial Intelligence (ChatGPT-4o) in Adjuvant Treatment Decision-Making for Stage II Colon Cancer: A Comparative Analysis with Clinician Recommendations and NCCN/ESMO Guidelines
KUŞ F., Chalabiyev E., YILDIRIM H. Ç., Koc Kus I., ŞİRVAN F., DİZDAR Ö., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.35, sa.1, ss.68-74, 2025 (SCI-Expanded, Scopus, TRDizin)
2025
20253. Comparative Analysis of Prognostic Potential of Pretreatment Blood-Based Biomarkers in Metastatic Bladder Cancer: Modified Glasgow Prognostic Score
KUŞ F., GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., Koc I., Tatar O. D., et al.
JOURNAL OF CLINICAL MEDICINE
, sa.6, 2025 (SCI-Expanded, Scopus)
2024
20244. Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer
YILMAZ F., YAŞAR S., Tatar O. D., Yildirim H. C., Guven D. C., AKYILDIZ A., et al.
BMC CANCER
, cilt.24, sa.1, 2024 (SCI-Expanded, Scopus)
2024
20245. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma
Yildirim H. C., BAYRAM E., Chalabiyev E., Majidova N., Avci T., Guzel H. G., et al.
JOURNAL OF CHEMOTHERAPY
, 2024 (SCI-Expanded, Scopus)
2024
20246. Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology Group
AKYILDIZ A., GÜLTEKİN M., YİĞİT E., Demir E., Ismayilov R., AHMED M. A., et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
, cilt.34, ss.1359-1365, 2024 (SCI-Expanded, Scopus)
2024
20247. Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab
YILDIRIM H. Ç., Anik H., ATEŞ ÖZDEMİR D., Ismayilov R., AKYILDIZ A., ÇAYIRÖZ K., et al.
BIOMOLECULES AND BIOMEDICINE
, cilt.24, sa.4, ss.998-1003, 2024 (SCI-Expanded, Scopus)
2024
20248. The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer
YILDIRIM H. Ç., Buyukkor M., KAVGACI G., ŞAHİN ÇELİK B., BİR YÜCEL K., DURSUN B., et al.
MEDICINE
, cilt.103, sa.30, 2024 (SCI-Expanded, Scopus)
2024
20249. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study
Yıldırım H. Ç., KUTLU Y., Mutlu E., Aykan M. B., Korkmaz M., Yalçın S., et al.
International Journal of Clinical Oncology
, cilt.29, sa.3, ss.258-265, 2024 (SCI-Expanded, Scopus)
2024
202410. Acute heart failure following pazopanib treatment: a literature review featuring two case reports
KERTMEN N., KAVGACI G., YILDIRIM H. Ç., DİZDAR Ö.
Anti-Cancer Drugs
, cilt.35, sa.3, ss.302-304, 2024 (SCI-Expanded, Scopus)
2024
202411. Sirolimus experience in adult patients with vascular malformations
AKYILDIZ A., Ismayilov R., GÜVEN D. C., YILDIRIM H. Ç., Tatar O. D., KUŞ F., et al.
Vascular
, 2024 (SCI-Expanded, Scopus)
2024
202412. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study
YILDIRIM H. Ç., Kapar C., KÖKSAL B., Seyyar M., Sanci P. C., Guliyev M., et al.
Journal of Chemotherapy
, 2024 (SCI-Expanded, Scopus)
2024
202413. The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional Study
KUŞ F., GÜVEN D. C., YILDIRIM H. Ç., Akagunduz B., Karakaya S., SÜTCÜOĞLU O., et al.
INTEGRATIVE CANCER THERAPIES
, cilt.23, 2024 (SCI-Expanded, Scopus)
2023
202314. A meta-analysis of the association between adjuvant chemoradiotherapy and disease-free survival in gastric cancer according to the histology
YILDIRIM H. Ç., GÜVEN D. C., AKYILDIZ A., YALÇIN Ş., DİZDAR Ö.
Irish Journal of Medical Science
, cilt.192, sa.6, ss.2631-2634, 2023 (SCI-Expanded, Scopus)
2023
202315. PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study
Avcı O., İriağaç Y., Çavdar E., Karaboyun K., Araz M., Şakalar T., et al.
Journal of Geriatric Oncology
, cilt.14, sa.8, 2023 (SCI-Expanded, Scopus)
2023
202316. A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancer
YILDIRIM H. Ç., Ismayilov R., AKYILDIZ A., GÜVEN D. C., Abdurrahimli N., DİZDAR Ö., et al.
Anti-cancer drugs
, cilt.34, sa.10, ss.1190-1192, 2023 (SCI-Expanded, Scopus)
2023
202317. Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab
YILDIRIM H. Ç., KUŞ F., GÜVEN D. C., Karaca E., KAYGUSUZ Y., DİZDAR Ö., et al.
Journal of Immunotherapy and Precision Oncology
, cilt.6, sa.4, ss.170-176, 2023 (Scopus)
2023
202318. Advances in the Early Detection of Hepatobiliary Cancers
YILDIRIM H. Ç., KAVGACI G., Chalabiyev E., DİZDAR Ö.
Cancers
, cilt.15, sa.15, 2023 (SCI-Expanded, Scopus)
2023
202319. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors
GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., et al.
Anti-Cancer Drugs
, cilt.34, sa.6, ss.783-790, 2023 (SCI-Expanded, Scopus)
2023
202320. SMART syndrome: a case report
Bozkurt S., Toprak B., YILDIRIM H. Ç., PARLAK SAĞOL Ş., GÜVEN D. C., KERTMEN N., et al.
ACTA NEUROLOGICA BELGICA
, cilt.123, sa.3, ss.1137-1140, 2023 (SCI-Expanded, Scopus)
2023
202321. Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort
AKYILDIZ A., GÜVEN D. C., YILDIRIM H. Ç., Ismayilov R., YILMAZ F., Tatar O. D., et al.
Medicine (United States)
, cilt.102, sa.18, 2023 (SCI-Expanded, Scopus)
2023
202322. The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma
GÜVEN D. C., ERUL E., YILMAZ F., YAŞAR S., YILDIRIM H. Ç., ERCAN F., et al.
European Archives of Oto-Rhino-Laryngology
, cilt.280, sa.5, ss.2471-2478, 2023 (SCI-Expanded, Scopus)
2023
202323. KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer
KUŞ F., Guven D. C., YILDIRIM H. Ç., Chalabiyev E., AKYILDIZ A., Tatar O. D., et al.
Biomarkers in Medicine
, cilt.17, sa.7, ss.379-389, 2023 (SCI-Expanded, Scopus)
2023
202324. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy
GÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., et al.
INTERNATIONAL JOURNAL OF CANCER
, cilt.152, ss.679-685, 2023 (SCI-Expanded, Scopus)
2023
202325. Knowledge and Protective Behaviors of Teachers on Skin Cancer: A Cross-Sectional Survey Study from Turkey
Kus C., Kus M. M., Keten H. S., Ucer H., Guvenc N., KUŞ F., et al.
Children
, cilt.10, sa.2, 2023 (SCI-Expanded, Scopus)
2023
202326. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
GÜRSOY P., TATLI A. M., Erdem D., GÖKER E., Celik E., Demirci N. S., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
, cilt.149, sa.2, ss.865-875, 2023 (SCI-Expanded, Scopus)
2023
202327. Emerging treatment strategies in hepatobiliary cancer
GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., KUŞ F., YILMAZ F., YAŞAR S., et al.
Expert Review of Anticancer Therapy
, cilt.23, sa.3, ss.243-256, 2023 (SCI-Expanded, Scopus)
2023
202328. Leptomeningeal metastasis in primary uterine cervical cancer: a rare case and review of the literature
KAHVECİOĞLU A., Sari S. Y., YILDIRIM H. Ç., ARIK Z., GÜLTEKİN M., YILDIZ F.
Corrosion Science and Technology
, cilt.19, sa.3, ss.184-189, 2023 (ESCI, Scopus)
2023
202329. Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer
YILDIRIM H. Ç., ÜNER M., Yildiran Özmen T., Chalabiyev E., GÜVEN D. C., KUŞ F., et al.
Journal of Oncological Science
, cilt.9, sa.1, ss.33-37, 2023 (Scopus, TRDizin)
2023
202330. Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment
Guven D. C., YILDIRIM H. Ç., KUŞ F., Erul E., KERTMEN N., DİZDAR Ö., et al.
Expert Review of Anticancer Therapy
, cilt.23, sa.10, ss.1049-1059, 2023 (SCI-Expanded, Scopus)
2022
202231. Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study
YILDIRIM H. Ç., MUTLU E., Chalabiyev E., Ozen M., KESKİNKILIÇ M., ÖN S., et al.
BREAST
, cilt.66, ss.85-88, 2022 (SCI-Expanded, Scopus)
2022
202232. Bilateral primary breast lymphoma in a pregnant woman: a case report and literature review
YILDIRIM H. Ç., AKYILDIZ A., Ismayilov R., Demirok N., BENLİ B. S., Guven D. C., et al.
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY
, cilt.15, sa.4, ss.307-310, 2022 (ESCI, Scopus)
2022
202233. Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease
YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.
JOURNAL OF CLINICAL MEDICINE
, cilt.11, sa.17, 2022 (SCI-Expanded, Scopus)
2022
202234. The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy
GÜVEN D. C., ŞAHİN T. K., Erul E., ÇAKIR İ. Y., ÜÇGÜL E., YILDIRIM H. Ç., et al.
JOURNAL OF CLINICAL MEDICINE
, cilt.11, sa.15, 2022 (SCI-Expanded, Scopus)
2022
202235. Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study
Yekeduz E., Ozbay M. F., Caglayan D., Yildirim A., Erol C., Yildirim H. C., et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.40, sa.4, 2022 (SCI-Expanded, Scopus)
2022
202236. HER2-low breast cancer could be associated with an increased risk of brain metastasis
GÜVEN D. C., KAYA M. B., Fedai B., ÖZDEN M., YILDIRIM H. Ç., KÖSEMEHMETOĞLU K., et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
, cilt.27, sa.2, ss.332-339, 2022 (SCI-Expanded, Scopus)
2022
202237. Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy
YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
, cilt.6, sa.1, ss.59-63, 2022 (ESCI, TRDizin)
2022
202238. The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study
GÜVEN D. C., YILDIRIM H. Ç., ERUL E., ŞAHİN T. K., ÇAKIR İ. Y., AKTEPE O. H., et al.
TURKISH JOURNAL OF MEDICAL SCIENCES
, cilt.52, sa.5, ss.1551-1558, 2022 (SCI-Expanded, Scopus, TRDizin)
2022
202239. Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)
Erol C., Sakin A., Başoglu T., Özden E., ÇABUK D., Doğan M., et al.
Turkish Journal of Medical Sciences
, cilt.52, sa.4, ss.1022-1032, 2022 (SCI-Expanded, Scopus, TRDizin)
2022
202240. Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy
YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., et al.
Journal of Oncological Science
, cilt.8, sa.3, ss.143-147, 2022 (Scopus, TRDizin)
2021
202141. A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer
GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., AKTEPE O. H., DİZDAR Ö., YALÇIN Ş.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
, cilt.168, 2021 (SCI-Expanded, Scopus)
2021
202142. The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy
AKTEPE O. H., GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇELİKTEN B., Yeter H. H., et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
, cilt.73, sa.10, ss.1957-1963, 2021 (SCI-Expanded, Scopus)
2021
202143. Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality
GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., Incesu F. G. G., TAHILLIOĞLU Y., et al.
BMJ SUPPORTIVE & PALLIATIVE CARE
, 2021 (SCI-Expanded, Scopus)
2021
202144. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy
GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al.
SUPPORTIVE CARE IN CANCER
, cilt.29, sa.9, ss.5417-5423, 2021 (SCI-Expanded, Scopus)
2021
202145. Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report
GÜVEN D. C., KILIÇKAP S., YILDIRIM H. Ç., Ceylan F., BAŞ O., DİZDAR Ö.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.27, sa.5, ss.1281-1283, 2021 (SCI-Expanded, Scopus)
2021
202146. Impact of coronaphobia on treatment and follow-up compliance of cancer patients
Akagunduz B., Ozer M., Karacin C., Atci M. M., YILDIRIM H. Ç., Unver E.
FUTURE ONCOLOGY
, cilt.17, ss.2621-2629, 2021 (SCI-Expanded, Scopus)
2021
202147. Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma
AKTEPE O. H., GÜNER G., GÜVEN D. C., TABAN H., YILDIRIM H. Ç., ŞAHİN T. K., et al.
TURKISH JOURNAL OF UROLOGY
, cilt.47, sa.2, ss.113-119, 2021 (ESCI, Scopus, TRDizin)
2021
202148. Assessment of Prognostic Factors and Adjuvant Treatment Modalities in Adult Head and Neck Soft Tissue Sarcoma Patients Treated With Upfront Surgery
Akagunduz B., AKIN TELLİ T., SEZGİN GÖKSU S., YILDIRIM H. Ç., Ozer M., Aydin S. G., et al.
CUREUS
, cilt.13, sa.2, 2021 (ESCI)
2021
202149. Factors Affecting Survival in Retroperitoneal Sarcomas Treated with Upfront Surgery: A Real-World Study by Turkish Oncology Group
Akagunduz B., AKIN TELLİ T., YILDIRIM H. Ç., SEZGİN GÖKSU S., DEMİR N., Hafizoglu E., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.31, sa.2, ss.92-98, 2021 (SCI-Expanded, Scopus, TRDizin)
2020
202050. Perspectives, Knowledge, and Fears of Cancer Patients About COVID-19
GÜVEN D. C., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., AKSOY S., KILIÇKAP S.
FRONTIERS IN ONCOLOGY
, cilt.10, 2020 (SCI-Expanded, Scopus)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
2024
20241. The efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: A multicenter study by the Turkish Oncology Group (TOG)
Akyildiz A., GÜLTEKİN M., Yigit E., Demir E., Ismayilov R., AHMED M. A., et al.
Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri)